Shares of biotech bluebird bio (NASDAQ: BLUE) are up 7.3% at 12:24 p.m. EDT, having been up as much as 16.3% today, after the company disclosed data in its abstracts for the American Society of Hematology (ASH) meeting in December. Being focused on blood diseases, basically the biotech’s entire pipeline is being covered at ASH, from gene therapy for sickle-cell disease and beta-thalassemia to its CAR-T bb2121 program.